Hidradenitis Suppurativa News

SAN DIEGO — It is important for both patients and dermatologists to know that there are options for the management of hidradenitis suppurativa during pregnancy, according to a speaker at the American Academy of Dermatology Annual Meeting.

Izokibep achieved the primary endpoint of ACR50 response in a phase 2b/3 psoriatic arthritis trial, and demonstrated sustained, “deepening” benefit in hidradenitis suppurativa, according to top-line data from its manufacturer.

SAN DIEGO — Lutikizumab showed positive results in the treatment of patients with hidradenitis suppurativa that failed anti-TNF treatment, according to a late-breaking presentation at the 2024 American Academy of Dermatology Annual Meeting.

The use of intravenous antibiotics, specifically ertapenem, was associated with improvement in inflammatory markers in patients with hidradenitis suppurativa, according to a study.

Data showed that not all patients with chronic inflammatory skin diseases undergo pretreatment testing before initiating systemic immunomodulatory therapies, despite current guidelines, according to a study.

MIAMI BEACH, Fla. — Janus kinase inhibitors have a unique mechanism of action, giving them the potential to push the boundaries of efficacy in the treatment of inflammatory skin diseases, according to a speaker at South Beach Symposium.

Patients with hidradenitis suppurativa are hesitant to use adalimumab — which is recommended as a first-line treatment for the skin condition — as well as other biologics, according to a study.

In addition to cutting edge content, the 22nd annual South Beach Symposium has added a “unique session” that focuses on how the medical and cosmetic dermatologist can work together to holistically treat patients.

Orismilast may improve mild to severe hidradenitis suppurativa; however, further studies are needed to confirm patient tolerability in this indication, according to a study.

Phase 2 trial results found lutikizumab was efficacious in treating hidradenitis suppurativa in patients who had previously failed anti-tumor necrosis factor therapy, AbbVie announced in a press release.